[Natural history, complications, safety and pregnancy in inflammatory bowel disease]

Gastroenterol Hepatol. 2015 Sep:38 Suppl 1:20-31. doi: 10.1016/S0210-5705(15)30016-9.
[Article in Spanish]


Numerous studies were presented in Digestive Disease Week 2015 (DDW 2015) on the natural history, complications, and safety of treatments in inflammatory bowel disease (IBD), as well as novel findings on fertility, pregnancy, and breastfeeding. The present article reviews presentations on the natural history of IBD, the risk of complications and their prevention, treatment safety, aspects related to fertility, pregnancy, and breastfeeding, as well as the risk of cancer and its association with IBD and with drugs used in its treatment. In the next few years, more data will become available on treatment safety and the possible complications that can develop in IBD patients due to the disease itself and the drugs employed in its treatment, which will allow measures to be adopted to improve prognosis.

Keywords: Anti-TNF; Cancer; Colitis ulcerosa; Crohn's disease; Cáncer; Embarazo; Enfermedad de Crohn; Enfermedad inflamatoria intestinal; Immunosuppressive drugs; Infecciones; Infections; Inflammatory bowel disease; Inmunosupresores; Pregnancy; Ulcerative colitis; Vedolizumab.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use
  • Clostridioides difficile
  • Clostridium Infections / epidemiology
  • Clostridium Infections / etiology
  • Constriction, Pathologic / etiology
  • Constriction, Pathologic / therapy
  • Disease Susceptibility
  • Female
  • Fertility
  • Fetus / drug effects
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Inflammatory Bowel Diseases / complications
  • Inflammatory Bowel Diseases / drug therapy
  • Inflammatory Bowel Diseases / physiopathology*
  • Lactation
  • Latent Tuberculosis / complications
  • Latent Tuberculosis / diagnosis
  • Meta-Analysis as Topic
  • Neoplasms / epidemiology
  • Neoplasms / etiology
  • Pregnancy
  • Pregnancy Complications / drug therapy
  • Pregnancy Complications / physiopathology*
  • Prognosis
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Vaccination


  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • vedolizumab